Amount of qualified clients: CDEC reviewed the uncertainty in the quantity of people with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as obtaining delicate or moderate condition might have a extreme bleeding phenoty